
Gene therapy clinical holds take centre stage
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.